ABCA1 p.Arg1068His
[switch to full view]Comments [show]
None has been submitted yet.
PMID: 21763656
[PubMed]
Suetani RJ et al: "Homology modeling and functional testing of an ABCA1 mutation causing Tangier disease."
No.
Sentence
Comment
0
Atherosclerosis 218 (2011) 404-410 Contents lists available at ScienceDirect Atherosclerosis journal homepage: www.elsevier.com/locate/atherosclerosis Homology modeling and functional testing of an ABCA1 mutation causing Tangier disease Rachel J. Suetania , Brie Sorrensona , Joel D.A. Tyndallb , Michael J.A. Williamsc , Sally P.A. McCormicka,* a Department of Biochemistry, University of Otago, Dunedin, New Zealand b School of Pharmacy, University of Otago, Dunedin, New Zealand c Department of Medical and Surgical Sciences, University of Otago, Dunedin, New Zealand a r t i c l e i n f o Article history: Received 27 January 2011 Received in revised form 8 June 2011 Accepted 8 June 2011 Available online 29 June 2011 Keywords: ABCA1 HDL Cholesterol efflux Homology modeling Tangier disease a b s t r a c t Objective: To investigate the impact of the p.R1068H mutation on the structure and function of the ATP-binding cassette A1 (ABCA1) protein.
X
ABCA1 p.Arg1068His 21763656:0:858
status: NEW2 Cholesterol efflux assays were performed on fibroblasts obtained from members of a Tangier disease (TD) family carrying the p.R1068H mutation and in HEK293 cells transfected with a p.R1068H mutant cDNA vector.
X
ABCA1 p.Arg1068His 21763656:2:126
status: NEWX
ABCA1 p.Arg1068His 21763656:2:183
status: NEW3 Confocal microscopy was used to investigate the localisation of the wildtype and mutant p.R1068H protein in HEK293 cells.
X
ABCA1 p.Arg1068His 21763656:3:90
status: NEW5 Cholesterol efflux studies showed the efflux from TD fibroblasts and HEK293 cells expressing the mutant p.R1068H protein to be markedly reduced compared to wildtype.
X
ABCA1 p.Arg1068His 21763656:5:106
status: NEW6 Localisation of the mutant p.R1068H protein in HEK293 cells showed intracellular retention of the protein indicating a defect in trafficking to the plasma membrane.
X
ABCA1 p.Arg1068His 21763656:6:29
status: NEW7 Conclusion: Homology modeling of the ABCA1 protein showed that the p.R1068H mutation would likely disrupt the conformation of NBD-1.
X
ABCA1 p.Arg1068His 21763656:7:69
status: NEW8 Functional studies of p.R1068H showed a lack of cholesterol efflux function due to defective trafficking to the plasma membrane, most likely caused by impaired oligomerisation.
X
ABCA1 p.Arg1068His 21763656:8:24
status: NEW26 We previously reported a missense mutation (c.3516G>A) in exon 22 of the ABCA1 gene, causing a p.R1068H amino acid substitution in a highly conserved region of the ABCA1 protein [11].
X
ABCA1 p.Arg1068His 21763656:26:97
status: NEW28 Heterozygotes with the p.R1068H mutation displayed a wide range of HDL levels (0.48-1.22 mmol L-1) [11].
X
ABCA1 p.Arg1068His 21763656:28:25
status: NEW31 doi:10.1016/j.atherosclerosis.2011.06.019 model for the human ABCA1 protein in order to better predict the effect of the p.R1068H mutation.
X
ABCA1 p.Arg1068His 21763656:31:126
status: NEW32 This was followed with direct testing of the functional impact of the p.R1068H mutation on the ABCA1 protein via cholesterol efflux assays and analysis of sub-cellular localisation.
X
ABCA1 p.Arg1068His 21763656:32:72
status: NEW34 Materials and methods 2.1. Computational modeling The functional impact of the p.R1068H substitution was predicted with the PANTHER [12] and SIFT [13] programmes, using the NCBI reference sequence NP005493.2.
X
ABCA1 p.Arg1068His 21763656:34:81
status: NEW38 Study subjects We have previously described the p.R1068H proband and her extended pedigree [11].
X
ABCA1 p.Arg1068His 21763656:38:50
status: NEW50 Mutagenic primers were used to introduce the c.3516G>A nucleotide change in exon 22 of the ABCA1 sequence causing the p.R1068H mutation.
X
ABCA1 p.Arg1068His 21763656:50:120
status: NEW78 Results 3.1. Computational analysis of p.R1068H Previous computational analysis of the p.R1068H mutation using PolyPhen suggested that the mutation was 'probably damaging` [11], however, further analysis of the mutation here using PANTHER and SIFT predicted the mutation to be 'damaging` and 'tolerated`, respectively.
X
ABCA1 p.Arg1068His 21763656:78:41
status: NEWX
ABCA1 p.Arg1068His 21763656:78:89
status: NEW109 Functional activity of the p.R1068H protein Cholesterol efflux assays in primary fibroblast cultures established from the TD subject showed a markedly reduced efflux compared to wildtype family members (0.9% versus 7.3%; Fig. 2A).
X
ABCA1 p.Arg1068His 21763656:109:29
status: NEW110 Heterozygous carriers of the p.R1068H mutation displayed an intermediate level of cholesterol efflux (2.9%) which was significantly lower than wildtype.
X
ABCA1 p.Arg1068His 21763656:110:29
status: NEW113 ABCA1 protein levels in both unstimulated and stimulated cells appeared unaffected by the presence of the p.R1068H mutation (Fig. 2C and D).
X
ABCA1 p.Arg1068His 21763656:113:108
status: NEW114 This was confirmed by quantification of triplicate Western blots that showed no significant difference in ABCA1 protein levels in p.R1068H heterozygotes versus wildtype fibroblasts under unstimulated (Fig. 2E) or stimulated (Fig. 2F) conditions.
X
ABCA1 p.Arg1068His 21763656:114:108
status: NEWX
ABCA1 p.Arg1068His 21763656:114:132
status: NEW116 The presence of the p.R1068H mutation did not affect ABCA1 expression, as the levels of wildtype R1068 and the mutant H1068 protein were comparable (Fig. 3A).
X
ABCA1 p.Arg1068His 21763656:116:22
status: NEW117 Cholesterol efflux assays showed that HEK293 cells expressing the p.R1068H vector had markedly reduced cholesterol efflux compared to cells Fig. 3.
X
ABCA1 p.Arg1068His 21763656:117:22
status: NEWX
ABCA1 p.Arg1068His 21763656:117:68
status: NEW119 Cultured HEK293 cells were transiently transfected with a GFP-tagged ABCA1 cDNA expression vector for either wildtype or p.R1068H.
X
ABCA1 p.Arg1068His 21763656:119:123
status: NEW127 Indeed, there was no statistical difference in cholesterol efflux between nontransfected HEK293 cells and cells expressing the mutant p.R1068H protein (p = 0.163), again confirming that the p.R1068H mutation renders the ABCA1 protein completely dysfunctional.
X
ABCA1 p.Arg1068His 21763656:127:136
status: NEWX
ABCA1 p.Arg1068His 21763656:127:192
status: NEW128 3.3. Sub-cellular localisation of the ABCA1 protein in vitro Confocal microscopy was used to investigate the effect of the p.R1068H mutation on localisation of the GFP-tagged ABCA1 protein.
X
ABCA1 p.Arg1068His 21763656:128:125
status: NEW130 Wildtype ABCA1 protein primarily localised to the extracellular membrane as expected while the p.R1068H ABCA1 protein localised to intracellular regions of the cells indicative of a defect in trafficking of the mutant protein (Fig. 4).
X
ABCA1 p.Arg1068His 21763656:130:97
status: NEW136 The p.R1068H mutation studied here was deemed to be damaging by PolyPhen and PANTHER, yet tolerated by SIFT.
X
ABCA1 p.Arg1068His 21763656:136:6
status: NEW137 Indeed, SIFT predicts any residue substitution at position 1068 to be tolerated except R1068W which does not align with the observation that p.R1068H and the p.R1068C mutation are associated with extremely reduced HDL levels [11,23].
X
ABCA1 p.Arg1068His 21763656:137:143
status: NEW139 For these reasons, we constructed a model of the dimeric NBDs of ABCA1 based on the crystal structure of the E. coli HlyB ABC transporter in order to visualise the p.R1068H mutation in a three-dimensional context.
X
ABCA1 p.Arg1068His 21763656:139:166
status: NEW141 The three dimensional model indicates potential ionic interactions between R1068 and two adjacent carboxylic acid containing residues, D1092 and E1093, which would be disrupted by the p.R1068H mutation.
X
ABCA1 p.Arg1068His 21763656:141:186
status: NEW143 The p.R1068H mutation does not appear to affect expression or stability of the ABCA1 protein as shown by Western blot analysis of both primary human fibroblasts and transfected HEK293 cells.
X
ABCA1 p.Arg1068His 21763656:143:6
status: NEW148 Preliminary studies investigating the oligomerisation state of the p.R1068H mutant showed only limited formation of a tetramer band (>800 kDa) and no dimer (Supplementary Fig. 1).
X
ABCA1 p.Arg1068His 21763656:148:69
status: NEW150 Furthermore, higher molecular weight species were apparent with p.R1068H suggesting a tendency to aggregate.
X
ABCA1 p.Arg1068His 21763656:150:66
status: NEW151 This could potentially explain why a much lower amount of the p.R1068H protein was detected on native gels compared to wildtype, despite similar amounts of ABCA1 being detected under denaturing conditions (Supplementary Fig. 1).
X
ABCA1 p.Arg1068His 21763656:151:64
status: NEW152 Based on our model (Fig. 1B), we propose that the R1068H mutation disrupts the structure of the ABCA1 monomer around the ATP-binding site altering the conformation of NBD-1 to disrupt dimerisation and subsequent tetramer formation.
X
ABCA1 p.Arg1068His 21763656:152:50
status: NEW155 The virtual absence of HDL in the TD proband would indicate that the p.R1068H mutation was highly detrimental to ABCA1 function.
X
ABCA1 p.Arg1068His 21763656:155:71
status: NEW156 Functional testing of the p.R1068H mutation in primary fibroblast cell lines established from p.R1068H family members confirmed this, with the mutant protein failing to mediate efflux to apoA-I even after stimulation.
X
ABCA1 p.Arg1068His 21763656:156:28
status: NEWX
ABCA1 p.Arg1068His 21763656:156:96
status: NEW157 Cholesterol efflux assays were also performed in HEK293 cells with cDNA expression vectors for either wildtype or p.R1068H ABCA1.
X
ABCA1 p.Arg1068His 21763656:157:116
status: NEW158 These assays also confirmed that the p.R1068H protein was completely dysfunctional.
X
ABCA1 p.Arg1068His 21763656:158:39
status: NEW160 HEK293 cells were transiently transfected with GFP-tagged ABCA1 cDNA expression vectors for either wildtype or p.R1068H.
X
ABCA1 p.Arg1068His 21763656:160:113
status: NEW163 To conclude, functional studies confirm that the p.R1068H mutation produces a dysfunctional ABCA1 protein due to defective trafficking.
X
ABCA1 p.Arg1068His 21763656:163:51
status: NEW166 Acknowledgements We wish to thank the p.R1068H family members for their participation in this study.
X
ABCA1 p.Arg1068His 21763656:166:40
status: NEW51 Mutagenic primers were used to introduce the c.3516G>A nucleotide change in exon 22 of the ABCA1 sequence causing the p.R1068H mutation.
X
ABCA1 p.Arg1068His 21763656:51:120
status: NEW79 Results 3.1. Computational analysis of p.R1068H Previous computational analysis of the p.R1068H mutation using PolyPhen suggested that the mutation was 'probably damaging` [11], however, further analysis of the mutation here using PANTHER and SIFT predicted the mutation to be 'damaging` and 'tolerated`, respectively.
X
ABCA1 p.Arg1068His 21763656:79:41
status: NEWX
ABCA1 p.Arg1068His 21763656:79:89
status: NEW111 Heterozygous carriers of the p.R1068H mutation displayed an intermediate level of cholesterol efflux (2.9%) which was significantly lower than wildtype.
X
ABCA1 p.Arg1068His 21763656:111:31
status: NEW115 This was confirmed by quantification of triplicate Western blots that showed no significant difference in ABCA1 protein levels in p.R1068H heterozygotes versus wildtype fibroblasts under unstimulated (Fig. 2E) or stimulated (Fig. 2F) conditions.
X
ABCA1 p.Arg1068His 21763656:115:132
status: NEW118 Cholesterol efflux assays showed that HEK293 cells expressing the p.R1068H vector had markedly reduced cholesterol efflux compared to cells Fig. 3.
X
ABCA1 p.Arg1068His 21763656:118:68
status: NEW120 Cultured HEK293 cells were transiently transfected with a GFP-tagged ABCA1 cDNA expression vector for either wildtype or p.R1068H.
X
ABCA1 p.Arg1068His 21763656:120:123
status: NEW
PMID: 18617650
[PubMed]
Murphy AJ et al: "High-density lipoprotein reduces the human monocyte inflammatory response."
No.
Sentence
Comment
26
Study Subjects: Healthy and R1068H Tangier Family The study was approved by the Human Ethics committees of the Alfred Hospital and the University of Otago; informed consent was obtained from all donors.
X
ABCA1 p.Arg1068His 18617650:26:28
status: NEW104 Tangier Patient Derived Monocytes For simplification of comparison between members of the R1068H Tangier family, results are expressed as percentage of CD11b expression after activation with PMA.
X
ABCA1 p.Arg1068His 18617650:104:90
status: NEW138 Finally, we explored the antiinflammatory role of HDL and apoA-I in a Tangier disease subject along with a heterozygote subject and an unaffected member from the R1068H family.48 Tangier disease patients have a dysfunctional ABCA1 unable to support cholesterol efflux to apoA-I.49 The response of monocytes from the unaffected family member was similar to that of healthy subjects, monocytes from the heterozygote subject responded to both HDL and apoA-I albeit less than compared to monocytes of unaffected family member.
X
ABCA1 p.Arg1068His 18617650:138:132
status: NEWX
ABCA1 p.Arg1068His 18617650:138:162
status: NEW145 Acknowledgments We acknowledge Rachel Brace for her efforts in helping with the blood collection and providing medical care for the R1068H family.
X
ABCA1 p.Arg1068His 18617650:145:132
status: NEW19 Study Subjects: Healthy and R1068H Tangier Family The study was approved by the Human Ethics committees of the Alfred Hospital and the University of Otago; informed consent was obtained from all donors.
X
ABCA1 p.Arg1068His 18617650:19:28
status: NEW97 Tangier Patient Derived Monocytes For simplification of comparison between members of the R1068H Tangier family, results are expressed as percentage of CD11b expression after activation with PMA.
X
ABCA1 p.Arg1068His 18617650:97:90
status: NEW131 Finally, we explored the antiinflammatory role of HDL and apoA-I in a Tangier disease subject along with a heterozygote subject and an unaffected member from the R1068H family.48 Tangier disease patients have a dysfunctional ABCA1 unable to support cholesterol efflux to apoA-I.49 The response of monocytes from the unaffected family member was similar to that of healthy subjects, monocytes from the heterozygote subject responded to both HDL and apoA-I albeit less than compared to monocytes of unaffected family member.
X
ABCA1 p.Arg1068His 18617650:131:162
status: NEW
PMID: 18199144
[PubMed]
Slatter TL et al: "Novel rare mutations and promoter haplotypes in ABCA1 contribute to low-HDL-C levels."
No.
Sentence
Comment
7
Mutations were identified in five of the low-HDL subjects, three having novel variants (I659V, R2004K, and A2028V) and two with a previously identified variant (R1068H).
X
ABCA1 p.Arg1068His 18199144:7:161
status: NEW57 One mutation (R1068H), detected in two low-HDL subjects, had previously been identified in an Otago family with Tangier disease (25).
X
ABCA1 p.Arg1068His 18199144:57:14
status: NEW59 The R1068H mutation was predicted to be Ôprobably damaging`, the R2004K mutation Ôpossibly damaging` and the I659V and A2028V mutations Ôbenign`.
X
ABCA1 p.Arg1068His 18199144:59:4
status: NEW88 Of those subjects carrying ABCA1 mutations, two were heterozygous for the R1068H mutation that was previously identified in an Otago family with Tangier disease (25).
X
ABCA1 p.Arg1068His 18199144:88:74
status: NEW
PMID: 16225879
[PubMed]
Slatter TL et al: "Promoter haplotype of a new ABCA1 mutant influences expression of familial hypoalphalipoproteinemia."
No.
Sentence
Comment
3
A new mutation (R1068H) within the first ATP-binding domain was identified in homozygous form in the Tangier disease individual and was present in several family members.
X
ABCA1 p.Arg1068His 16225879:3:16
status: NEW35 (A) Pedigree and genotype of the R1068H family.
X
ABCA1 p.Arg1068His 16225879:35:33
status: NEW36 The proband with Tangier disease (represented by an arrow and filled circle) is homozygous for the R1068H mutation.
X
ABCA1 p.Arg1068His 16225879:36:99
status: NEW40 (B) Detection of the R1068H mutation by dHPLC.
X
ABCA1 p.Arg1068His 16225879:40:21
status: NEW41 The dHPLC profiles of the exon 22 amplicon of three members of the R1068H family are shown.
X
ABCA1 p.Arg1068His 16225879:41:67
status: NEW44 (C) Detection of the R1068H mutation by DNA sequencing.
X
ABCA1 p.Arg1068His 16225879:44:21
status: NEW47 The mutation predicts an arginine to histidine substitution at amino acid 1068 in the ABCA1 protein.
X
ABCA1 p.Arg1068His 16225879:47:25
status: NEW83 Statistical analysis The Mann-Whitney test was used to compare the mean differences in lipid levels in the presence and absence of the R1068H mutation and in the presence of the maternal versus paternal 1068H allele in heterozygotes.
X
ABCA1 p.Arg1068His 16225879:83:135
status: NEW89 An HDL-C measurement was not available Table 1 Plasma lipid levels and genotypes in the R1068H family Subject Sex Age TC TG LDL-C HDL-C R1068H II:2 M 76 5.40 1.20 3.50 1.37 -/- II:3 M 66 5.70 1.60 3.30 1.63 -/- II:4 F 67 6.07 2.62 3.75 1.12 +/- II:5a M 58 3.90 0.63 NT II:7 F 60 7.10 2.10 4.60 1.53 -/- II:8 M 66 5.10 2.60 3.30 0.60 +/- III:1 F 46 5.40 1.00 3.60 1.39 -/- III:3 F 42 3.50 1.50 2.80 0.04 +/+ III:4 M 38 4.00 0.60 2.50 1.22 +/- III:5 F 49 5.40 0.90 2.70 2.26 -/- III:6 M 48 6.50 2.02 4.60 1.00 -/- III:7 F 44 3.98 1.31 2.90 0.48 +/- III:8 F 40 7.50 1.42 5.85 1.08 -/- III:9 F 41 2.60 0.70 1.70 0.60 +/- III:10 F 37 4.50 1.10 3.10 0.90 +/- III:11 M 35 5.53 1.20 4.02 1.10 -/- IV:1 F 23 3.60 0.40 2.40 1.03 +/- IV:2 F 21 4.00 0.80 2.30 1.35 +/- IV:3 F 24 3.50 0.50 2.50 0.76 +/- TC indicates total cholesterol; TG, triglycerides; HDL-C, high-density cholesterol; LDL-C low-density cholesterol. All measurements are expressed in mmol/L.
X
ABCA1 p.Arg1068His 16225879:89:90
status: NEWX
ABCA1 p.Arg1068His 16225879:89:138
status: NEW90 (-/-) wildtype; (+/-) heterozygous for the R1068H mutation; (+/+) homozygote for the R1068H mutation.
X
ABCA1 p.Arg1068His 16225879:90:43
status: NEWX
ABCA1 p.Arg1068His 16225879:90:85
status: NEW104 (A) Schematic diagram showing the position of the R1068H mutation within the ATP-binding region of ABCA1.
X
ABCA1 p.Arg1068His 16225879:104:50
status: NEW106 (B) Alignment of the ABCA protein sequences from different species around the R1068H region.
X
ABCA1 p.Arg1068His 16225879:106:78
status: NEW111 A computer analysis of the effect of the R1068H mutation on ABCA1 function using PolyPhen (www.bork.embl-heidelberg.de/PolyPhen) predicts that the mutation is "possibly damaging".
X
ABCA1 p.Arg1068His 16225879:111:41
status: NEW114 Sequencing of exon 22 from the nine family members containing the exon 22 heteroduplex revealed them all to be heterozygous for the R1068H mutation (Fig. 1A).
X
ABCA1 p.Arg1068His 16225879:114:132
status: NEW115 The R1068H mutation was absent in all other family members.
X
ABCA1 p.Arg1068His 16225879:115:4
status: NEW136 Table 2 Mean plasma lipid and lipoprotein levels in the R1068H family based on genotype R1068H Genotype Sex Age TC TG LDL-C HDL-C M F -/- (n = 8) 4 4 53 ± 14 6.07 ± 0.85 1.43 ± 0.45 4.02 ± 0.98 1.42 ± 0.40 -/+ (n = 9) 7 2 40 ± 17 4.15 ± 0.99* 1.18 ± 0.86 2.72 ± 0.61** 0.90 ± 0.31*** -/+m (n = 4) 1 4 37 ± 21 4.42 ± 1.12 1.10 ± 1.02 2.74 ± 0.68 1.18 ± 0.14 -/+p (n = 5) 1 3 42 ± 15 3.94 ± 0.96**** 1.24 ± 0.82 2.70 ± 0.63***** 0.67 ± 0.16******,******* TC indicates total cholesterol; TG, triglycerides; HDL-C, high-density cholesterol; LDL-C low-density cholesterol. All measurements are expressed in mmol/L.
X
ABCA1 p.Arg1068His 16225879:136:56
status: NEWX
ABCA1 p.Arg1068His 16225879:136:88
status: NEW137 (-/-), wildtype; (+/-), heterozygous for the R1068H mutation; (-/+m), heterozygous for the maternal R1068H allele; (-/+p), heterozygous for the paternal R1068H allele.
X
ABCA1 p.Arg1068His 16225879:137:45
status: NEWX
ABCA1 p.Arg1068His 16225879:137:100
status: NEWX
ABCA1 p.Arg1068His 16225879:137:153
status: NEW151 A further analysis of lipid levels based on genotype (Table 2) revealed a significantly lower mean total cholesterol, LDL-C and HDL-C in R1068H heterozygotes compared to unaffected family members (4.15 ± 0.99 mmol/L versus 6.07 ± 0.85 mmol/L, p = 0.003; 2.72 ± 0.61 mmol/L versus 4.02 ± 0.98 mmol/L, p = 0.006 and 0.90 ± 0.31 mmol/L versus 1.42 ± 0.40 mmol/L, p = 0.012, respectively).
X
ABCA1 p.Arg1068His 16225879:151:137
status: NEW159 In the current study, we report a new mutation (R1068H) within the first ATP-binding cassette of ABCA1.
X
ABCA1 p.Arg1068His 16225879:159:48
status: NEW165 Since the R1068H mutation is likely to produce a dysfunctional protein, one would expect it to be associated with FHA in the heterozygous state.
X
ABCA1 p.Arg1068His 16225879:165:10
status: NEW187 Furthermore, a recent sequence analysis of the 3 untranslated region of both R1068H alleles has revealed a SNP(NCBISNPIDNumberrs4149341)inthepaternalallele (T Slatter, unpublished data), which strengthens the case for non-consanguinity.
X
ABCA1 p.Arg1068His 16225879:187:77
status: NEW
PMID: 16704350
[PubMed]
Brunham LR et al: "Variations on a gene: rare and common variants in ABCA1 and their impact on HDL cholesterol levels and atherosclerosis."
No.
Sentence
Comment
555
Since a complete loss of function allele would be expected to result in a 50% reduction in HDL levels, a greater than 50% reduction in HDL is most likely explained by a dominant negative allele, in which TABLE 3 Patient phenotypes associated with heterozygous ABCA1 mutations Mutation HDL (mmol/L) HDL (% of control) Number of patients M1091T 0.48 ± 0.5 30 ± 30 4 G1216V 0.50 40 1 R2144X 0.56 ± 0.2 41 ± 18 12 R282X 0.52 41 1 R909X 0.59 ± 0.3 42 ± 19 5 K776N 0.55 ± 0.1 47 ± 5 2 R587W 0.61 ± 0.1 47 ± 8 7 S364C 0.60 48 1 P1065S 0.80 51 1 c-ter deletion 0.75 53 1 N1800H - 56.5 33 P85L 0.72 ± 0.4 57 ± 33 5 Del693L 0.79 ± 0.2 57 ± 15 8 D1289N 0.80 ± 0.1 59 ± 12 4 R2081W 0.80 ± 0.1 59 ± 12 4 2203X 0.80 ± 0.2 59 ± 20 4 DelED1893,4 0.77 ± 0.2 59 ± 18 8 2145X 0.82 ± 0.1 59 ± 9 4 A1046D 0.70 ± 0.1 60 ± 8 2 Q597R 0.82 ± 0.1 60 ± 5 5 C1477R 0.82 ± 0.2 61 ± 15 9 IVS25 + 1G > C 0.78 ± 0.1 62 ± 12 4 D1099Y 0.83 ± 0.3 63 ± 21 5 1552X 1.00 64 1 F2009S 0.82 ± 0.2 64 ± 19 6 R587W 0.86 ± 0.1 65 ± 17 2 R1068H 0.90 ± 0.3 67 ± 26 9 N935S 1.00 ± 0.3 74 ± 16 7 T929I 1.01 ± 0.2 76 ± 7 8 1284X 1.11 ± 0.2 83 ± 14 5 A937V 1.15 ± 0.6 85 ± 28 2 R1680W 1.22 ± 0.2 87 ± 17 3 635X 1.24 ± 0.5 90 ± 32 7 W590S 1.32 ± 0.6 103 ± 46 15 the mutant protein actually interferes with the activity of the remaining wild-type protein.
X
ABCA1 p.Arg1068His 16704350:555:1186
status: NEW562 Support for this concept comes from a recent study showing that HDL cholesterol levels in carriers of the R1068H mutation are significantly influenced by the ABCA1 promoter haplotype associated with the mutation (100).
X
ABCA1 p.Arg1068His 16704350:562:106
status: NEW
PMID: 23087442
[PubMed]
Sorrenson B et al: "Functional rescue of mutant ABCA1 proteins by sodium 4-phenylbutyrate."
No.
Sentence
Comment
16
Nine different ABCA1 mutants (p.A594T, p.I659V, p.R1068H, p.T1512M, p.Y1767D, p.N1800H, p.R2004K, p.A2028V, p.Q2239N) expressed in HEK293 cells, displaying different degrees of mislocalization to the plasma membrane and discrete impacts on cholesterol efflux, were subject to treatment with 4-PBA.
X
ABCA1 p.Arg1068His 23087442:16:50
status: NEW18 In fibroblast cells obtained from low HDL-C subjects expressing two of the ABCA1 mutants (p.R1068H and p.N1800H), 4-PBA increased cholesterol efflux without any increase in ABCA1 expression.
X
ABCA1 p.Arg1068His 23087442:18:92
status: NEW53 The Pearson`s correlation coefficient between the GFP and AlexaFluor594 of the ABCA1 mutations were previously identified in low HDL-C subjects and included three uncharacterized mutations, p.I659V, p.R2004K, and p.A2028V (18) and three variants, p.R1068H, p.T1512M, and p.N1800H, known to have reduced localization and cholesterol efflux (19, 20).
X
ABCA1 p.Arg1068His 23087442:53:249
status: NEW85 4-PBA rescues mutant ABCA1 localization and improves cholesterol efflux function in transfected HEK293 cells 4-PBA treatment was applied to the six uncharacterized ABCA1 mutants as well as to three mutants that we have previously shown to have reduced cholesterol efflux function, p.R1068H (19), p.T1512M (20), and p.N1800H (20, Fig. 1).
X
ABCA1 p.Arg1068His 23087442:85:283
status: NEW109 Upon 4-PBA treatment, efflux function was significantly increased relative to the untreated level for the p.R1068H, p.T1512M, p.Y1767D, p.N1800H, p.R2004K, and p.A2028V mutants (Fig. 3B).
X
ABCA1 p.Arg1068His 23087442:109:108
status: NEW112 Treatment with 4-PBA induced a significant increase in colocalization for the p.A594T, p.R1068H, p.T1512M, p.Y1767D, p.N1800H, and p.R2004K mutants. Treatment with 4-PBA did not affect the colocalization of the wild-type ABCA1-GFP protein (supplementary Fig. II).
X
ABCA1 p.Arg1068His 23087442:112:89
status: NEW122 Fibroblasts were obtained from two p.R1068H heterozygote carriers (RH1 and RH2), two p.N1800H heterozygote carriers (NH1 and NH2), and two ABCA1 wild-type subjects (WT1 and WT2).
X
ABCA1 p.Arg1068His 23087442:122:37
status: NEW126 However, the cholesterol efflux of the p.R1068H mutant was unable to be restored to wild-type levels.
X
ABCA1 p.Arg1068His 23087442:126:41
status: NEW141 In contrast, there was a clear trend for increased efflux in the mutants fibroblast cells with statistically significant increases for the p.R1068H heterozygote RH1 (p < 0.05) and the p.N1800H heterozygote NH2 (p < 0.001).
X
ABCA1 p.Arg1068His 23087442:141:141
status: NEW156 Fibroblast cultures established from wild-type (WT1, WT2), p.R1068H carriers (RH1, RH2) and p.N1800H carriers (NH1, NH2) were treated with 10 mM 4-PBA for 24 h.
X
ABCA1 p.Arg1068His 23087442:156:61
status: NEW164 For example, the p.Y1767D mutant showed a much enhanced localization and dramatic increase in cholesterol efflux after 4-PBA treatment whereas the efflux function for the p.R1068H mutant remained low despite showing a similar enhancement in localization.
X
ABCA1 p.Arg1068His 23087442:164:173
status: NEW165 The p.R1068H mutant, located in the first ATP binding domain, has been shown to be defective in oligomerisation (19) and it is likely that although localization was improved for this mutant with 4-PBA treatment, the oligomerisation and therefore efflux function remained defective.
X
ABCA1 p.Arg1068His 23087442:165:6
status: NEW185 The magnitude by which 4-PBA rescued function was mutant-dependent as restored localization did not always result in a restoration of function, as was the case for the p.R1068H mutant.
X
ABCA1 p.Arg1068His 23087442:185:170
status: NEW188 For two of the most dramatically affected mutants, p.R1068H and p.N1800H, a functional improvement with 4-PBA treatment was also confirmed ex vivo using primary fibroblast cells.
X
ABCA1 p.Arg1068His 23087442:188:53
status: NEW201 The authors thank the p.R1068H and p.N1800H family members for their participation in this study. We are grateful to Professor Christiane Albrecht for kindly providing the pCIneo-ABCA1-GFP expression vector.
X
ABCA1 p.Arg1068His 23087442:201:24
status: NEW
PMID: 26616730
[PubMed]
Murano T et al: "Subfraction analysis of circulating lipoproteins in a patient with Tangier disease due to a novel ABCA1 mutation."
No.
Sentence
Comment
123
Arg1068His has been identified to cause Tangier disease [24, 25].
X
ABCA1 p.Arg1068His 26616730:123:0
status: NEW